The anti-invasive activity of fisetin occurred through inhibition of BRAF-MEK-ERK (MAPK) and NFκB signaling pathways (Figure 7), which are aberrantly activated in a majority of metastatic melanomas. The gene discussed is BRAF; the disease is metastatic melanoma.